WO2010026299A1 - Methods and means for soft tissue engineering - Google Patents
Methods and means for soft tissue engineering Download PDFInfo
- Publication number
- WO2010026299A1 WO2010026299A1 PCT/FI2009/050715 FI2009050715W WO2010026299A1 WO 2010026299 A1 WO2010026299 A1 WO 2010026299A1 FI 2009050715 W FI2009050715 W FI 2009050715W WO 2010026299 A1 WO2010026299 A1 WO 2010026299A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- extract
- adipose tissue
- implant
- tissue
- ate
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 34
- 210000004872 soft tissue Anatomy 0.000 title claims abstract description 28
- 239000007943 implant Substances 0.000 claims abstract description 95
- 210000000577 adipose tissue Anatomy 0.000 claims abstract description 92
- 239000000284 extract Substances 0.000 claims abstract description 85
- 230000033115 angiogenesis Effects 0.000 claims abstract description 21
- 230000011759 adipose tissue development Effects 0.000 claims abstract description 17
- 230000017423 tissue regeneration Effects 0.000 claims abstract description 11
- 230000001939 inductive effect Effects 0.000 claims abstract description 8
- 230000000302 ischemic effect Effects 0.000 claims abstract description 8
- 208000014674 injury Diseases 0.000 claims abstract description 7
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 6
- 230000006378 damage Effects 0.000 claims abstract description 6
- 230000029663 wound healing Effects 0.000 claims abstract description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 57
- 108090000623 proteins and genes Proteins 0.000 claims description 57
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 37
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims description 37
- 229920002674 hyaluronan Polymers 0.000 claims description 20
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 19
- 239000003102 growth factor Substances 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 19
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 17
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims description 17
- 229960003160 hyaluronic acid Drugs 0.000 claims description 17
- 239000011159 matrix material Substances 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 8
- 229920001661 Chitosan Polymers 0.000 claims description 7
- 102100026262 Metalloproteinase inhibitor 2 Human genes 0.000 claims description 7
- 108010031372 Tissue Inhibitor of Metalloproteinase-2 Proteins 0.000 claims description 7
- 108010076365 Adiponectin Proteins 0.000 claims description 6
- 102000011690 Adiponectin Human genes 0.000 claims description 6
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims description 6
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims description 6
- 102000008186 Collagen Human genes 0.000 claims description 6
- 108010035532 Collagen Proteins 0.000 claims description 6
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 6
- 101000973997 Homo sapiens Nucleosome assembly protein 1-like 4 Proteins 0.000 claims description 6
- 101000947178 Homo sapiens Platelet basic protein Proteins 0.000 claims description 6
- 108090001005 Interleukin-6 Proteins 0.000 claims description 6
- 102100036154 Platelet basic protein Human genes 0.000 claims description 6
- 108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 claims description 6
- 229920001436 collagen Polymers 0.000 claims description 6
- 102100022987 Angiogenin Human genes 0.000 claims description 5
- 102100032367 C-C motif chemokine 5 Human genes 0.000 claims description 5
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 claims description 5
- 102000016267 Leptin Human genes 0.000 claims description 5
- 108010092277 Leptin Proteins 0.000 claims description 5
- 102000034655 MIF Human genes 0.000 claims description 5
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 5
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 5
- 108010072788 angiogenin Proteins 0.000 claims description 5
- 229940039781 leptin Drugs 0.000 claims description 5
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims description 5
- 102000004883 Insulin-like growth factor-binding protein 6 Human genes 0.000 claims description 4
- 108090001014 Insulin-like growth factor-binding protein 6 Proteins 0.000 claims description 4
- 108010002616 Interleukin-5 Proteins 0.000 claims description 4
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 claims description 4
- -1 lL-8 Proteins 0.000 claims description 4
- 239000004632 polycaprolactone Substances 0.000 claims description 4
- 239000004626 polylactic acid Substances 0.000 claims description 4
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 3
- 108010081589 Becaplermin Proteins 0.000 claims description 3
- 102000009123 Fibrin Human genes 0.000 claims description 3
- 108010073385 Fibrin Proteins 0.000 claims description 3
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 3
- 108060004872 MIF Proteins 0.000 claims description 3
- 229940072056 alginate Drugs 0.000 claims description 3
- 229920000615 alginic acid Polymers 0.000 claims description 3
- 235000010443 alginic acid Nutrition 0.000 claims description 3
- 229960005188 collagen Drugs 0.000 claims description 3
- 229950003499 fibrin Drugs 0.000 claims description 3
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 3
- 229920000728 polyester Polymers 0.000 claims description 3
- 102000005353 Tissue Inhibitor of Metalloproteinase-1 Human genes 0.000 claims description 2
- 239000000560 biocompatible material Substances 0.000 claims description 2
- 229940045110 chitosan Drugs 0.000 claims description 2
- 101150093802 CXCL1 gene Proteins 0.000 claims 2
- 235000003625 Acrocomia mexicana Nutrition 0.000 claims 1
- 244000202285 Acrocomia mexicana Species 0.000 claims 1
- 102100034221 Growth-regulated alpha protein Human genes 0.000 claims 1
- 230000006698 induction Effects 0.000 abstract description 10
- 238000002360 preparation method Methods 0.000 abstract description 7
- 238000011282 treatment Methods 0.000 abstract description 5
- 210000004027 cell Anatomy 0.000 description 45
- 210000001519 tissue Anatomy 0.000 description 44
- 241000282414 Homo sapiens Species 0.000 description 32
- 230000002293 adipogenic effect Effects 0.000 description 22
- 238000011534 incubation Methods 0.000 description 22
- 239000000463 material Substances 0.000 description 20
- 230000015572 biosynthetic process Effects 0.000 description 19
- 238000005755 formation reaction Methods 0.000 description 19
- 239000000017 hydrogel Substances 0.000 description 16
- 238000002513 implantation Methods 0.000 description 16
- 230000002491 angiogenic effect Effects 0.000 description 14
- 210000000130 stem cell Anatomy 0.000 description 14
- 102000004127 Cytokines Human genes 0.000 description 13
- 108090000695 Cytokines Proteins 0.000 description 13
- 241000700159 Rattus Species 0.000 description 13
- 239000002609 medium Substances 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 12
- 230000007547 defect Effects 0.000 description 12
- 239000001963 growth medium Substances 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- 230000000975 bioactive effect Effects 0.000 description 10
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 230000009772 tissue formation Effects 0.000 description 10
- 210000001789 adipocyte Anatomy 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 206010033675 panniculitis Diseases 0.000 description 9
- 239000013641 positive control Substances 0.000 description 9
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 8
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 8
- 239000002543 antimycotic Substances 0.000 description 8
- 230000004069 differentiation Effects 0.000 description 8
- 230000007998 vessel formation Effects 0.000 description 8
- 229930182816 L-glutamine Natural products 0.000 description 7
- 239000002870 angiogenesis inducing agent Substances 0.000 description 7
- 239000006143 cell culture medium Substances 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 239000012266 salt solution Substances 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 6
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 6
- 102000013462 Interleukin-12 Human genes 0.000 description 6
- 108010065805 Interleukin-12 Proteins 0.000 description 6
- 230000009815 adipogenic differentiation Effects 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 210000002744 extracellular matrix Anatomy 0.000 description 6
- 210000002950 fibroblast Anatomy 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000007443 liposuction Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 102000004889 Interleukin-6 Human genes 0.000 description 5
- 206010029113 Neovascularisation Diseases 0.000 description 5
- 229920001954 Restylane Polymers 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 5
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 231100000241 scar Toxicity 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 102000001301 EGF receptor Human genes 0.000 description 4
- 108060006698 EGF receptor Proteins 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 108700012411 TNFSF10 Proteins 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 210000002808 connective tissue Anatomy 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 210000002889 endothelial cell Anatomy 0.000 description 4
- 230000003511 endothelial effect Effects 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 239000011859 microparticle Substances 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- 102000054930 Agouti-Related Human genes 0.000 description 3
- 101710127426 Agouti-related protein Proteins 0.000 description 3
- 102100021936 C-C motif chemokine 27 Human genes 0.000 description 3
- 102100032366 C-C motif chemokine 7 Human genes 0.000 description 3
- 102100034871 C-C motif chemokine 8 Human genes 0.000 description 3
- 108010083675 Chemokine CCL27 Proteins 0.000 description 3
- 102000000013 Chemokine CCL3 Human genes 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 description 3
- 108090000381 Fibroblast growth factor 4 Proteins 0.000 description 3
- 102000003968 Fibroblast growth factor 6 Human genes 0.000 description 3
- 108090000382 Fibroblast growth factor 6 Proteins 0.000 description 3
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 3
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 101150088952 IGF1 gene Proteins 0.000 description 3
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 3
- 108010064600 Intercellular Adhesion Molecule-3 Proteins 0.000 description 3
- 102100037871 Intercellular adhesion molecule 3 Human genes 0.000 description 3
- 102000000589 Interleukin-1 Human genes 0.000 description 3
- 108010002352 Interleukin-1 Proteins 0.000 description 3
- 102000003815 Interleukin-11 Human genes 0.000 description 3
- 108090000177 Interleukin-11 Proteins 0.000 description 3
- 102000013691 Interleukin-17 Human genes 0.000 description 3
- 108050003558 Interleukin-17 Proteins 0.000 description 3
- 102100039897 Interleukin-5 Human genes 0.000 description 3
- 102000003683 Neurotrophin-4 Human genes 0.000 description 3
- 108090000099 Neurotrophin-4 Proteins 0.000 description 3
- 102100035194 Placenta growth factor Human genes 0.000 description 3
- 102100037236 Tyrosine-protein kinase receptor UFO Human genes 0.000 description 3
- 108010073919 Vascular Endothelial Growth Factor D Proteins 0.000 description 3
- 102100038234 Vascular endothelial growth factor D Human genes 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 108010023337 axl receptor tyrosine kinase Proteins 0.000 description 3
- 239000012620 biological material Substances 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000003862 glucocorticoid Substances 0.000 description 3
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 3
- 229940099552 hyaluronan Drugs 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 229920001610 polycaprolactone Polymers 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 235000019624 protein content Nutrition 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 101710155834 C-C motif chemokine 7 Proteins 0.000 description 2
- 101710155833 C-C motif chemokine 8 Proteins 0.000 description 2
- 108700012434 CCL3 Proteins 0.000 description 2
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 2
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 2
- 101001001487 Homo sapiens Phosphatidylinositol-glycan biosynthesis class F protein Proteins 0.000 description 2
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 2
- 102000004374 Insulin-like growth factor binding protein 3 Human genes 0.000 description 2
- 108090000965 Insulin-like growth factor binding protein 3 Proteins 0.000 description 2
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 2
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 2
- 102000004890 Interleukin-8 Human genes 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- 108040000066 TRAIL receptor activity proteins Proteins 0.000 description 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 2
- 230000035508 accumulation Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- AEUKDPKXTPNBNY-XEYRWQBLSA-N mcp 2 Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)C1=CC=CC=C1 AEUKDPKXTPNBNY-XEYRWQBLSA-N 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 229920005615 natural polymer Polymers 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 210000003668 pericyte Anatomy 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000036573 scar formation Effects 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 description 1
- BNIFSVVAHBLNTN-XKKUQSFHSA-N (2s)-4-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-1-[(2s)-4-amino-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s,3r)-2-amino-3-hydroxybutanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexan Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(O)=O)CCC1 BNIFSVVAHBLNTN-XKKUQSFHSA-N 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
- 241001316595 Acris Species 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102100034608 Angiopoietin-2 Human genes 0.000 description 1
- 108010048036 Angiopoietin-2 Proteins 0.000 description 1
- 102100022717 Atypical chemokine receptor 1 Human genes 0.000 description 1
- 238000000035 BCA protein assay Methods 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102100036842 C-C motif chemokine 19 Human genes 0.000 description 1
- 102100021935 C-C motif chemokine 26 Human genes 0.000 description 1
- 101710155856 C-C motif chemokine 3 Proteins 0.000 description 1
- 102100021984 C-C motif chemokine 4-like Human genes 0.000 description 1
- 102100025279 C-X-C motif chemokine 11 Human genes 0.000 description 1
- 101710098272 C-X-C motif chemokine 11 Proteins 0.000 description 1
- 108010082161 Chemokine CCL19 Proteins 0.000 description 1
- 108010083698 Chemokine CCL26 Proteins 0.000 description 1
- 108010055165 Chemokine CCL4 Proteins 0.000 description 1
- 108010055124 Chemokine CCL7 Proteins 0.000 description 1
- 108010055204 Chemokine CCL8 Proteins 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 102100032813 Hepatocyte growth factor-like protein Human genes 0.000 description 1
- 101000678879 Homo sapiens Atypical chemokine receptor 1 Proteins 0.000 description 1
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 1
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102100035304 Lymphotactin Human genes 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 108010048043 Macrophage Migration-Inhibitory Factors Proteins 0.000 description 1
- 102100037791 Macrophage migration inhibitory factor Human genes 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 1
- 101000597780 Mus musculus Tumor necrosis factor ligand superfamily member 18 Proteins 0.000 description 1
- 101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000008108 Osteoprotegerin Human genes 0.000 description 1
- 108010035042 Osteoprotegerin Proteins 0.000 description 1
- 108010082093 Placenta Growth Factor Proteins 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102000036693 Thrombopoietin Human genes 0.000 description 1
- 108010041111 Thrombopoietin Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 1
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 1
- 102100031358 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 239000012578 cell culture reagent Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- YRQNKMKHABXEJZ-UVQQGXFZSA-N chembl176323 Chemical compound C1C[C@]2(C)[C@@]3(C)CC(N=C4C[C@]5(C)CCC6[C@]7(C)CC[C@@H]([C@]7(CC[C@]6(C)[C@@]5(C)CC4=N4)C)CCCCCCCC)=C4C[C@]3(C)CCC2[C@]2(C)CC[C@H](CCCCCCCC)[C@]21C YRQNKMKHABXEJZ-UVQQGXFZSA-N 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 210000001608 connective tissue cell Anatomy 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 102000028718 growth factor binding proteins Human genes 0.000 description 1
- 108091009353 growth factor binding proteins Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 102000044162 human IGF1 Human genes 0.000 description 1
- 102000058223 human VEGFA Human genes 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 108010021426 hylan gel Proteins 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000012760 immunocytochemical staining Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940074383 interleukin-11 Drugs 0.000 description 1
- 229940117681 interleukin-12 Drugs 0.000 description 1
- 229940100602 interleukin-5 Drugs 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 229940096397 interleukin-8 Drugs 0.000 description 1
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 229940039412 ketalar Drugs 0.000 description 1
- VCMGMSHEPQENPE-UHFFFAOYSA-N ketamine hydrochloride Chemical compound [Cl-].C=1C=CC=C(Cl)C=1C1([NH2+]C)CCCCC1=O VCMGMSHEPQENPE-UHFFFAOYSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 108010019677 lymphotactin Proteins 0.000 description 1
- 108010053292 macrophage stimulating protein Proteins 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- VPNGEIHDPSLNMU-UHFFFAOYSA-N medetomidine hydrochloride Chemical compound Cl.C=1C=CC(C)=C(C)C=1C(C)C1=CNC=N1 VPNGEIHDPSLNMU-UHFFFAOYSA-N 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 229940097998 neurotrophin 4 Drugs 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 108010012038 peptide 78 Proteins 0.000 description 1
- 229940125863 peptide 78 Drugs 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000003868 tissue accumulation Effects 0.000 description 1
- 239000002407 tissue scaffold Substances 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 102000009816 urokinase plasminogen activator receptor activity proteins Human genes 0.000 description 1
- 108040001269 urokinase plasminogen activator receptor activity proteins Proteins 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 210000000264 venule Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/52—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the present invention relates to soft tissue engineering. More precisely, the present invention is directed to an acellular adipose tissue extract, an implant comprising said extract, methods for their preparation and uses thereof.
- Soft tissue consists of connecting and supporting structures in the body such as muscles, connective tissue, adipose tissue and blood ves- sels.
- Soft tissue engineering seeks to fabricate replacement parts for soft tissue defects resulting from e.g. trauma (burns and scars), surgical resection or congenital malformations.
- cosmetic use such as filling of facial wrinkles, is an important application of reconstituted soft tissue.
- Alloplastic materials such as silicon and bovine collagen, have been used in tissue engineering. Such materials may, however, cause severe rejection reactions, as well as allergic reactions. Thus, the use of natural transplant materials is nowadays preferred.
- Autologous transplants would be desirable for use in soft tissue engineering.
- Autologous adipose tissue transplantation is an old therapeu- tic procedure, where mature adipocytes or adipose tissue itself are transplanted into the site of defect.
- Adipose tissue is abundant, easy to collect, and readily obtainable for clinical uses.
- the use of autologous adipose tissue transplants may still result in several problems such as resorption, excessive connective tissue (scar) formation, inflammation reactions, as well as hardening and clotting of the transplant.
- long-term results obtained with adipose tissue transplantation are unpredictable and variable, depending on the method used and the skills of the person executing said method.
- Adipose stem cells have been used for soft tissue engineer- ing. Such cells are capable of proliferating and differentiating into mature adipose tissue. However, as the extracellular matrix has an essential role in cell proliferation and differentiation, it is unlikely that repair of large or deep soft tissue defects would be possible with cells alone. In order to be regenerated into functional tissue, transplanted cells need an artificial extracellular matrix, i.e. biomaterial scaffold to aid in cell attachment, proliferation and differentiation.
- adipogenesis is a promising approach to soft tissue engineering.
- the present invention is based on studies attempting to provide a microenvironment that is suitable for ceil proliferation and differentiation, thus resulting in formation of adipose tissue without exogenous transplantation of cells.
- An optimal microenvironment enhances migration of adipose stem cells from the surrounding tissue and induces the cells to differentiate into mature adipocytes.
- Neovascularization in the developing tissue is required to avoid necrosis, scar formation and resorbtion of transplanted tissue, as well as to secrete several differentiation factors.
- the present invention provides a ceilfree adipose tissue extract, comprising a predetermined amount of VEGF, FGF-2, and IGF-1.
- the extract comprises at least 1 pg of VEGF, at least 70 pg of FGF-2, and at least 50 pg of IGF-1 per 1 mg of total protein.
- the VEGF content per 1 mg of total protein is at least 7 pg.
- the extract may be used in soft tissue repair or engineering and in angiogenesis induction in tissue engineering e.g. in wound healing, in treating burn injuries and in treating ischemic conditions.
- the present invention further provides an implant comprising a celifree adipose tissue extract according to any embodiment of the invention and a biocompatible matrix.
- the extract is preferably allogenic, whereas the matrix is preferably a hydroge! and may be selected from a group consisting of hyaluronic acid, chitosan, fibrin, collagen, alginate, polyesters based on poly lactic acid, poly lactic glycolic acid, polycaproiactone, and mixtures thereof.
- the implant is injectable.
- the impiant may be used in soft tissue repair or engineering and in angiogenesis induction in tissue engineering e.g. in wound healing, in treating burn injuries and in treating ischemic conditions.
- the present invention still further provides a method of pre- paring a cellfree adipose tissue extract according to any embodiment of the invention.
- the method comprises the steps of a) providing a non-homogenized adipose tissue sample comprising viable cells, b) incubating said sample a predetermined time, and c) collecting the extract. Further provided is the cell- free adipose tissue extract obtainable said method.
- the present invention provides a method of preparing an implant according any embodiment of the invention. The method comprises mixing the adipose tissue extract with, or absorbing the same into, a biocompatible material.
- the present invention provides a method of in- ducing adipogenesis and a method of inducing angiogenesis.
- the methods comprise implanting into a subject in need thereof an implant according to any appropriate embodiment of the invention.
- Figure 1 illustrates tota! protein and growth factor contents in adipose tissue extracts according to the present invention.
- Figure 1A shows the total protein concentration in 20 randomly selected human adipose tissue extracts at different time points.
- Figures 1 B, 1 C, and 1 D show the concentrations of IGF-1 , FGF-2 and VEGF, respectively, in human adipose tissue extracts (ATE) at different time points.
- a mean is shown as a bar in each figure.
- Figure 2 illustrates adipogenic differentiation of human adipose stem cells (hASCs).
- Figure 2A shows hASCs grown in a control growth medium.
- Figure 2B shows hASCs growing in an ATE medium containing about 350 ⁇ g/ml protein, 2C about 700 ⁇ g/mi protein, and 2D about 1200 ⁇ g/ml of protein.
- ATE treatments have dose-dependent potential of adipogenesis induction.
- Figure 3 demonstrates tube formation in an angiogenesis assay.
- Figure 3A represents a negative control showing no tube formation.
- Figures 3B and 3C represent ceils treated with 900 ⁇ g/ml (protein content) or 1300 ⁇ g/ml of ATE, respectively.
- Figure 3D shows positive control cells, treated with known angiogenic growth factors, 10 ng/ml of VEGF and 1 ng/ml of FGF-2. Tube formation can be clearly seen in 3B, 3C 1 and 3D. Both ATE treatments have equal but dose-dependent potential of angiogenesis induction as compared to the angiogenic potential of the positive control 3D.
- Figure 4 illustrates vascularization and adipose tissue formation in vivo in rat subcutis at 2 weeks after implantation of an implant according to the present embodiments.
- Figures 4A and 4B show extensive capillary for- mation in the implant area.
- Figures 4C and 4D show large arteriole-like structures as well as some adipose tissue development. Examples of vessels are shown by arrows.
- Figure 5 illustrates massive adipose tissue formation at 12 weeks (5A and 5B) and 20 weeks (5C and 5D) after implantation of the implant according to the present embodiments.
- the implant is shown by arrows in 5B and 5D.
- Figure 6 illustrates a clinical pretrial showing human subcutis and its adipose tissue formation and vascularization after implantation the implant according to the present embodiments beneath an old scar tissue in a leg.
- Figure 6A shows the tissue before implantation.
- Figure 6B shows the subcutis at three months after implantion.
- Figure 6C shows upper subcutis vessel formation at six months.
- Figure 6D shows the adipose tissue and vascularization in the subcutis just below the dermis at six months.
- the tissue mass has at least doubled at six months, and adipose tissue and large vessels have devei- oped.
- Adipose tissue comprises adipocytes of various differentiation states, endothelial cells, fibroblasts, pericytes as well as adipose stem cells and mesenchymal stem cells that are capable of differentiating into sev- eral lineages of cells.
- De novo adipogenesis i.e. formation of new adipose tis- sue, is a promising approach to soft tissue engineering.
- the present invention is based on studies attempting to provide a microenvironment that is suitable for cell proliferation and differentiation, thus resulting in formation of biood vessels and adipose tissue without exogenous transplantation of cells.
- An optimal microenvironment enhances migration of adipose stem cells from the surrounding tissue and induces differentiation of endothelial and adipocyte precursor cells into mature adipocytes, loose connective tissue and muscle cells and vascular cells.
- Neovascularization in the developing tissue is always required to avoid necrosis and scar formation, i.e. in order to enable the func- tionai mature adipose tissue to develop.
- the present invention relates to a cellfree adipose tissue extract (ATE) having potential for inducing rapid formation of adipose tissue and vasculature at the site of implantation without administration of ceils.
- ATE cellfree adipose tissue extract
- the ATE is capable of creating an optima! microenvironment for de novo adipogenesis and angiogenesis and may thus be used in soft tissue repair and/or engineering.
- ATE adipose tissue extract
- adipose tissue extract refers to a mixture of bioactive substances, preferably adipogenic and angiogenic factors, secreted by the adipose tissue cells, i.e. adipocytes of various differentiation states, endothelial cells, fibroblasts, pericytes as well as adipose stem cells.
- the extract is cellfree or acellular.
- the adipose tissue extract differs from a traditional conditioned medium, for instance, in that the extract is collected from small tissue pieces or viable cells.
- the preparation process includes no cell culturing, the resulting extract is much more concentrated than a condi- tioned medium, and the incubation time is short varying from several minutes to a couple of days.
- Adipose tissue extract may be prepared from fat or adipose tissue sample obtained e.g. from liposuction or a surgical operation. If necessary, the tissue sample is cut into small pieces such that the cells remain sub- stantialiy viable. Liposuction material may be used directly. In other words, processing of the tissue sample does not involve homogenization.
- the bioactive factors are extracted by incubating cells in a culture medium, in a sterile salt solution, in a phosphate buffered saline or in other suitable isotonic aqueous buffer solutions where cells or tissue pieces release bioactive factors into the liquid phase during incubation.
- the ATE i.e. liquid phase without cells is then collected.
- the ATE may also be filtered prior to use to sterilize the extract and to create aceilular liquid.
- the resulting ATE is a cell-free protein mixture of cytokines and other bioactive substances.
- allogenic adipose tissue may be used as a source of an ATE, and processed to that end as described above.
- Such allogenic extracts couid be absorbed into and used in e.g. freeze- dried "off-the-shelf soft tissue scaffolds.
- One example of a product of this kind is made from crossfinked hyaluronic acid (e.g. Restyiane) and allogenic ATE. Since the extract is aceilular, immune responses and allergic reactions are unlikely even in allogenic use where the same extract and implant suits several patients. This is supported by animal studies described in more detail in Example 5, where human ATE implanted in rats (xenograft) did not cause any inflammation reactions or other complications.
- ATE is an optimal cytokine mixture of adipogenic and angiogenic factors that are expressed by the cells of adipose tissue.
- Bioactive substances of ATE may be measured by routine methods known in the art (e.g. ELISA).
- ELISA electroactive immunosorbent assay for determining the ability of cytokines to differentiate adipogenic cells into adipogenic cells.
- 120 cytokines in various ATEs was measured (see Example 1 ). Long incubation time, such as 24 hours or more, resulted in a more angiogenic extract, whereas both short and long incubation times produced an adipogenic mixture.
- An ATE may be tailored to comprise desired, or predetermined, amounts of adipogenic and angiogenic factors, including a vascular endothelial cell growth factor (VEGF), basic fibroblast growth factor (FGF-2), and insulin- like growth factor (IGF-1 ).
- VEGF vascular endothelial cell growth factor
- FGF-2 basic fibroblast growth factor
- IGF-1 insulin- like growth factor
- the desired composition may depend on the intended use.
- VEGF and FGF-2 are regarded as important factors for stimulating angiogenesis, whereas FGF-2 and IGF are important for stimulating adipogenesis.
- the ATE comprises at least 1 pg of VEGF, at least 70 pg of FGF-2, and at least 50 pg of IGF-1 per 1 mg of total protein.
- Such an ATE is particularly suitable for stimulating adipogenesis e.g. in soft tissue repair and engineering.
- the ATE comprises at least 7 pg of VEGF, at least 70 pg of FGF-2, and at least 50 pg of IGF-1 per 1 mg of total protein.
- This kind of an ATE is particularly usefu! in stimulating angiogenesis e.g. in inducing wound healing and treating ischemic conditions and burn injuries.
- Different tailored ATEs may further contain differ- ent amounts of several other cytokines although they may not always be crucial for the specific application (see Table 1 ). In general, ATE should contain about 2:1 to about 1 :2 IGF-1 and FGF-2, and about 1 :100 to about 1:10 VEGF and FGF-2.
- the content of an adipose tissue extract may be tailored by using different incubation times and temperatures in the preparation of the ATE.
- the incubation time ranges from a few minutes to several hours, such as overnight.
- an incubation time of about 1 hour typically results in a total protein content of about 1.7 mg/mi to about 2.5 mg/ml, IGF-1 content of about 200 pg/ml to about 1300 pg/mj, FGF-2 content of about 200 pg/mi to about 1400 pg/ml, and VEGF content of about 2 pg/ml to about 25 pg/mi.
- incubation time of 1 hour results typically in IGF-1 content of about 150 pg to about 550 pg per 1 mg of total protein, in FGF-2 content of about 100 pg to about 500 pg per 1 mg of total protein, and in VEGF content of about 3 pg to about 20 pg per 1 mg of total protein.
- This type of extract is both adipogenic and angiogenic. If, however, an especially high con- centration of VEGF (about 200 pg/ml to about 1400 pg/ml, that is about 25 pg to about 500 pg of VEGF per 1 mg of protein) is desirable in the extract, e.g.
- the incubation time should be extended e.g. to about 24 hours. Incubation time of 24 hour results typically in iGF-1 content of about 60 pg to about 200 pg per 1 mg of total protein, in FGF-2 content of about 130 pg to about 500 pg per 1 mg of total protein, and in VEGF content of about 25 pg to about 500 pg per 1 mg of total protein.
- various incubation temperatures typically ranging from room temperature to about 37°C, may be used to modify the adipose tissue extract. In some embodiments, however, lower temperatures such as 4 0 C may be used. In still other embodiments higher temperatures may be used as long as the proteins will not denaturate.
- the concentration of VEGF in the extract may vary between about 1 pg/mi and about 1400 pg/ml, and preferably between about 10 pg/ml to about 1000 pg/ml, more preferably between about 7 pg/ml to about 700 pg/ml, and most preferably between about 10 pg/ml to about 100 pg/rml.
- the concentration of FGF-2 in the extract may vary between about 20 pg/ml to about 1500 pg/ml, preferably between about 100 pg/ml to about 1300 pg/ml, more preferably between about 150 pg/ml to about 1000 pg/ml, and most preferably between about 200 pg/ml to about 800 pg/ml.
- the concentration of IGF-1 may vary between about 100 pg/ml to about 1500 pg/ml, and preferably between about 150 pg/ml to about 800 pg/ml, and most preferabiy between about 200 pg/m! to about 500 pg/mi.
- the total protein concentration of the extract may vary between about 0.75 mg/ml and about 3.5 mg/ml.
- the total protein concentration is about 1.4 mg/ml to about 2.7mg/ml, more preferably about 1.8 mg/ml to about 2.7 mg/ml, and even more preferably about 2 mg/ml to about 2.7 mg/ml, and most preferably about 2.1 mg/ml to about 2.5 mg/ml.
- the concentrations of the bioactive substances in the extract may also be defined in relation to the total protein concentration. Accordingly, the amount of VEGF in an extract containing 1 mg of total protein (growth fac- tor content per 1 mg of protein) may vary between about 1 pg and about 800 pg, and preferably between about 3.5 pg to about 500 pg, more preferably between about 7 pg to about 300 pg, and most preferably between about 20 pg to about 100 pg.
- the amount of FGF-2 in an extract containing about 1 mg of total protein may vary between about 1 pg to about 1200 pg, preferably between about 1 pg and about 600 pg, more preferably between about 70 pg to about 500 pg, and even more preferabiy between about 110 pg to about 450 pg, and most preferably between about 250 pg to about 350 pg.
- the amount of IGF- 1 may vary between about 50 pg to about 700 pg, and prefera- bly between about 100 pg to about 500 pg, and even more preferably between about 100 pg to about 300 pg, and most preferably between about 110 pg to about 230 pg.
- An ATE may further comprise several other adipogenic and angiogenic factors (presented in Table I) such as growth factors, interleukins, complement system products, glucocorticoids, prostaglandins, lipoproteins and free fatty acids as well as extracellular matrix components e.g. collagen I, collagen IV and collagen Vl, proteoglycans, elastin and hyaluronan either naturally or as added thereto to further tailor the ATE.
- the ATE may be supplemented, for instance, with any desired drugs or medicaments prior to use.
- an ATE may be further tailored by removing substances, such as single growth factors or cytokines, prior to use.
- substances such as single growth factors or cytokines
- inhibitors of angiogenesis such as T1MP-1 and TIMP-2
- primarily adipogenic factors such as IGF-I, adiponectin and/or leptin may be removed if the ATE is to be used for inducing primarily angiogenesis e.g. in treating ischemic conditions.
- Methods of removing or isolating desired substances are readily available in the art, including isolation of growth factors by immunoab- sorption.
- Tailoring an ATE may further include concentrating (e.g. by centrifugation) or diluting (e.g. with a cuiture medium, sterile physiological salt solution or any other buffered isotonic solution) in order to achieve a suitable ATE for a particular use.
- concentrating e.g. by centrifugation
- diluting e.g. with a cuiture medium, sterile physiological salt solution or any other buffered isotonic solution
- the angiogenic potential of the extract accord- ing to the present embodiments was assessed in a tubule formation assay in vitro.
- Human endothelial ceils were cultured on top of a fibroblast culture in the presence or absence of the adipose tissue extract, or VEGF and FGF-2.
- angiogenesis i.e. tube formation, was clearly observed as demonstrated in Figure 3 and described in more detail in Example 3.
- the angiogenic potential of the ATE was clearly dose dependent.
- an ATE according to the present invention may be used as a cell culture medium or ceil culture medium supplement to study adipogenesis or angiogenesis in vitro.
- the ATE results in even distribution of differentiated adipose cells in a ceil culture and, thus, provides an excellent ceil model for adipogenesis reflecting in vivo conditions in humans. To date, no adequate cell model for adipogenic differentiation exists.
- an ATE may be used as a cell culture component or as a serum substitute in a cell culture medium. This is not only cost-effective but useful for generating tissue engineered human constructs, especially when animal derived components are not suitable.
- the present invention further relates to an implant compris- ing an autologous or allogenic cellfree adipose tissue extract and a biocompatible matrix. Repair of large or deep soft tissue defects is difficult with the adipose tissue extract alone, but the implant provided is suitable for fiiiing the soft tissue defect, stands mechanical load, and also allows new tissue to be regenerated. Furthermore, the implant provides stable long-term results, feels and looks like a natural tissue, is easy to use, is nontoxic and inert but, on the other hand, allows adequate diffusion of nutrients and metabolites.
- the bio- combatible matrix must be non-toxic to humans, fairly inert in a tissue, able to bind and release small molecules (e.g. growth factors), and degradable in a tissue.
- Biocompatible matrices used in the implant according to the present invention are preferably hydrogels.
- hydrogel as used herein means a highly hydrated material which consists of hydrophilic polymer chains, is able to absorb water into its structure, swells hundreds or thousands per- cents of its original volume and stiii retains its structure.
- Natural polymer hydrogels have several promising properties. They are degradable, they can be processed in mild conditions and they either are components of the extracellular matrix (ECM) or have structural simiiarities therewith. Natural polymers are often non-toxic and interact well with the surrounding tissue in vivo. Hydrogel stiffness or rigidity, degradation rate, and bioactive substance binding or substance re-lease rate can be modified, depending on the demands of a specific implant. Methods for such modifications are readily available in the art.
- hyaluronic acid or hyalu- ronan
- hyaluronic acid or hyalu- ronan
- Hyaluronic acid is a commonly used natural biomateriai since it is quite nonimmunogenic and has been used safely for several decades in the field.
- Crosslinked hyaluronic acid is commercially available e.g. under the trade names Restylane® (Q-Med, Sweden), Elevess ® (Anika Therapeutics, USA), Juvederm ® (L.E.A.
- chitosan is a natural polysaccharide containing polymers of glucosa- mine and N-acetylglucosamine. Being a slowly biodegradable biomaterial and non-toxic to humans, chitosan has been extensively used as a pharmaceutical agent in the industry and research. Previously, modified chitosan has been used as a controlled release delivery system for hormones, drugs or proteins, wherein the release occurs both by diffusion and degradation of the biomaterial.
- Suitable natural hydrogel forming materials for use in the present invention are readily available to a person skilled in the art, and include e.g. collagen, alginate, gelatin, fibrin, and agarose.
- Synthetic hydrogeis such as polyesters based on poly lactic acid (PLA), poly lactic glycolic acid PLGA, polycaprolactone (PCL) may also be used as hydrogeis in the implants according to the embodiments of the present invention.
- adipogenesis or angiogenesis it may be possible to achieve more adipogenesis or angiogenesis.
- material modifications e.g. hyaluronan cross-linking
- An implant according to the present embodiments may also comprise a mixture of hydrogeis, such as a mixture of chitosan and hyaluronic acid. Hydrogeis may be combined by blending, copolymerizing, or functionaliz- ing.
- the biocompatible matrix may comprise nano- or microparticles.
- microparticles may be made from chitosan e.g. by an iongelation method, or synthetic PLA, PLGA or PCL microparticles may be produced by a water-oil-water method, and be mixed inside a second hydrogel material, e.g. hyaluronic acid.
- adipose tissue extract may be provided in both the nano- or microparticles and the hydrogel surrounding said particles in an implant.
- ATE may be combined with any degradable drug-release device.
- the amount of the biocompatible matrix in relation to the amount of the adipose tissue extract in the implant is typically about 37% to about 50% biocompatible matrix and about 50% to about 63% extract.
- the biocompatible matrix is a hydrogel, such as hyaluronic acid
- a drop in the hydrogel content in the implant leads to a weaker gel structure, resulting in a faster degradation rate in the body.
- the implant comprises about 45,5% hyaluronic acid and about 54,5% adipose tissue extract.
- Such an implant has a gel strength weak enough to allow injection directly into the recipient tissue.
- the hydrogel, or combinations thereof, may also be modified by cross-linking, freeze-drying, blending and/or copoiymerisation, and different concentrations of hydroge! combinations may be used.
- the size of the implant may also vary from very small (few microlitres) to several tens of m ⁇ li ⁇ tres. Typically, e.g. for facial reconstruction purposes, 1 to 5 miliiiitres of the implant is used.
- the adipose tissue extract content in the implant may vary.
- the implant comprises between about 300 ⁇ g/ml to about 1.2 mg/mi of protein, preferably between 600 ⁇ g/ml and 1 mg/ml, and even more prefera ⁇ bly close to 800 to 900 ⁇ g/ml.
- the implant according to the present invention may be im- planted by any suitable means. Injection offers a feasible method for implantation. Alternative forms of implantation are well known in the art, such as a scaffold, a film or a membrane.
- the adipogenic and angiogenic potential of an implant according to the present invention was verified in animal experiments.
- the im- plants were implanted under rat skin in vivo, and the adipose tissue and blood vessel formation were monitored at the implantation site (Example 4, Figure 4 and Figure 5).
- adipose tissue accumulation as well as vessel formation, were observed.
- extensive vessel formation and arte ⁇ al-like structures were seen in close contact with the implant, as well as some adipose tissue formation.
- a highly vascularized, thick, dense layer of mature adipose tissue was detected at a close contact with the implant.
- the implant had degraded; however, developed mature adipose tissue was still present, substantiating long-lasting results obtainable with the implants of the present embodiments.
- these results demonstrate that the implant according to the present embodiments can indeed be used for soft tissue engineering and repair in vivo.
- the present invention provides an implant which induces de novo adipose tissue formation and angiogenesis and provides a long-term delivery system of adipogenic and/or angiogenic factors that have been captured and immobilized into a hydrogel structure.
- the bioactive implant of the present invention aids in the induction of host cell infiltration and enables more efficient tissue regeneration.
- the effects of the implants are local and site-specific, reducing overall doses of adipogenic and angiogenic factors required for a certain effect. Not oniy is this cost-effective but also a way to avoid harmful systemic effects.
- the present invention further provides a method of preparing an implant according to the present invention.
- the method comprises mixing an adipose tissue extract with, or absorbing the same into, a biocompatible matrix.
- the mixing is typically performed carefully, avoiding air bubble formation, at room temperature in sterile syringes until ATE and the hydrogel mate- rial are completely mixed.
- the extract is immediately captured and absorbed into the hydrogel material and ready to be used for implantation.
- the present invention provides the use of an adipose tissue extract and an implant according to the present invention in soft tissue repair or engineering. Accordingly, the extract and the implant may be used in a method of repairing or engineering soft tissue to achieve development of mature adipose tissue and adequate vascularization. In one specific embodiment, the implant is administered by injection.
- the present invention provides the use of an adipose tissue extract and an implant according to the present invention in an- giogenesis induction and/or ischemic tissue repair.
- the extract and the implant may be used in a method of repairing or engineering capillaries to achieve development of adequate vascularization.
- the implant is administered by injection.
- adipogenesis usually the presence of existent fat cells or adipose tissue stem cells in a tissue is advantageous, if the implant is e.g. administered into a tissue with no adipose cells, the effect of the implant may be more or mostly angiogenic rather than adipogenic.
- One advantage of the present invention is that the preparation of ATE is easy and its tailoring is fast due to a short incubation time and short mixing time. Thus, the whole process of deriving an adipose tissue, processing it into an ATE and further into an implant, as well as implantation may be completed during one operation.
- ATE adipose tissue extract
- Extracts incubated in a sterile salt solution or in a cell culture medium had corresponding total protein contents.
- Optimal protein production was achieved when equal volumes of an incubation solution (medium or sterile salt solution) and a minced adipose tissue were used for the extraction.
- Such conditions re- suited in protein concentrations close to 2 mg/ml, which is in a proper range for cell culture studies. However, stronger concentrations may, and often have to be, diluted to a proper range. Any excess incubation solution resulted in too low protein concentrations that needed further modification by concentration in spin columns.
- VEGF vascular endothelial cell growth factor
- FGF-2 basic fibroblast growth factor
- IGF-1 insulin-like growth factor
- IGF-1 concentration was at its highest level after 1-hour incubation (Fig. 1 B), while FGF-2 concentration was quite high throughout the incubation (Fig. 1C).
- VEGF seemed to increase dramatically after 24 hours of culturing (Fig. 1 D). Though the VEGF concentration was adequate at 1 hour and 2 hours for adipogenesis or angiogenesis induction as tested, VEGF reached very high levels only after a 24-hour incubation.
- the cytokine pattern of ATE within the limits of detection of the array was as follows: the 1 hr ATE samples expressed high amounts of angiogenin, adiponectin, TIMP-1 and TIMP-2, MIF, SGFBP-6, NAP-2, leptin, PDGF-BB 1 GRO and small amounts of several other factors, shown in Table I. The 24 hr ATE samples expressed high amounts of angiogenin, IL-6, NAP-2, MCP-1 , adiponectin, GRO, TIMP-1 , TIMP-2 and small amounts of several other factors, shown in Table I. At 24 hours, over all, more cytokines were expressed than at 1 hour (see Table I).
- Leptin, PDGF-BB, MIF, and iGFBP-6 expressions were high at 1 hour, whereas Sow at 24 hours.
- MCP-1 , IL-6, CCL5 and VEGF expression was high, but only detected in low amount at 1 hour.
- AgRP agouti-related protein
- AxI AXL receptor tyrosine kinase
- CCL5 RANTES
- CTACK cutaneous T cell-attracting chemokine
- Dtk growth factor receptor tyrosine kinase
- EGF-R epidermal growth factor receptor
- ENA-78 epithelial neutrophil activating peptide-78
- EGF-R epidermal growth factor R
- FGF-2 fibroblast growth factor 2
- FGF-4 fibroblast growth factor 4
- FGF-6 fibroblast growth factor 6
- FGF-9 fibroblast growth factor 2
- GCSF granulocyte colony-stimulating factor
- GITR glucocorticoid-induced tumor necrosis factor receptor
- GITR- ligand glucocorticoid-induced tumor necrosis factor receptor ligand
- GRO cy- tokine
- hASC Human adipose derived stem cells
- the digested tissue was centrifuged at 600 x g for 10 minutes at room temperature.
- the digested tissue was first filtered through a filter having a pore size of 100 ⁇ m and then through a filter having a pore size of 40 ⁇ m.
- the human stem cell population obtained was cultured in DMEM/F12 supplemented with 15% human serum (HS, Cambrex), 1 mM L-glutamine, and 1 % antibiotic-antimycotic mixture (Gibco).
- the cells were maintained at 37 0 C under a 5% CO 2 air atmosphere at a constant humidity. The cells were allowed to attach over night. The next day, the cells were washed several times and the medium was changed to remove debris.
- hASCs were cultured as above and the medium was changed every two to three days. Early passage (p1 to p5) confluent stem cell cultures derived from two or three different patients were trypsinized, pooled together and plated in a culture medium at a density of 10 000 cells/cm 2 . The next day, six different culture conditions were applied:
- ATE (1200 ⁇ g/ml protein concentration; 83% of the final culture volume) supplemented with 15% human serum, 1 % antibiotic- antimycotic mixture, 1 mM L-glutamine;
- adipogenic medium DMEM/F12, 10 % fetal bovine serum (FBS), 1 % antibiotic-antimycotic mixture, 1 % L-glutamine, 33 M biotin, 17 M pantothenate, 100 nM insulin, 1 M dexamethasone (Sigma), and 0.25 mM isobutyl-methylxanthine (IBMX, Sigma). IBMX was left in the adipogenic cul- ture medium for the first 24 hours only.
- FBS fetal bovine serum
- IBMX isobutyl-methylxanthine
- the medium was changed every two to three days. At defined time points (2 to 3 weeks and 5 weeks) the adipogenic differentiation was evaluated by staining the eel! cultures with Oil-red-O (Sigma). Cell culture reagents were obtained from Gibco unless otherwise stated. [0075] Adipogenic differentiation in the different culture conditions was assessed based on triglyceride accumulation in the cells detected by Oil- red-0 staining. Briefly, 0.5% Oil-red-O solution was prepared by dissolving OiI- red-O in 100% isopropanol. The solution was mixed with distilled water in a ratio of 2:3 and left at room temperature for 10 minutes. The resulting solution was filtered using a standard filter paper.
- the cell culture media were aspired from the wells and the wells were rinsed gently with PBS two to three times.
- the ceils were fixed with 4% paraformaldehyde solution for 20 minutes.
- the wells were then rinsed with distilled water.
- the cells were incubated in 60% isopropanol solution for 2 to 5 minutes, after which previously prepared Oil-red-O solution was added and incubated for 5 minutes.
- the welis were rinsed with distilled water until the water was clear.
- Phase contrast micrographs of the stained ceils were taken with Nikon TS-100 connected to a CCD camera unit (Nikon, Tokyo, Japan). The amount of adipogenic differentiation was measured by evaluating the extent of red-stained area within the ceils.
- the adipose tissue extract was shown to induce a dose-dependent homogenic adipogenic conversion to a majority of the cells in the culture after 1 to 3 weeks in culture (Fig. 2).
- the adipogenic effect was seen when at least 200 ⁇ g/m! of ATE was used, and the adipogenic effect was more extensive when higher concentrations of ATE were tested, up to 2 mg/ml.
- the ATE used in the experiment was prepared as described in Example 1 , and contained 1.8 mg/ml protein, 143 pg/ml IGF-I, 123 pg/ml FGF-2, and 3.6 pg/ml VEGF.
- BJ fibroblasts (CRL-2522; American Type Culture Collection, Manassas, VA, USA,) were cultured in MEM (Gibco) supplemented with 10% fetal bovine serum, 1 % L-glutamine, 1 % non-essential amino acids ⁇ Gibco), and 1% antibiotic-antimycotic mixture (Gibco).
- MEM Gibco
- the cells were maintained at 37 0 C under a 5% CO2 air atmosphere at a constant humidity. The medium was changed every two to three days and confluent cells were split 1 :4.
- HAVEC Human umbilical vein endothelial cells
- EMM-2 Endothelial Growth Medium
- the cells were maintained at 37 0 C under a 5% CO 2 air atmosphere at a constant humidity.
- the medium was changed every two to three days and confluent cells were split 1 :4.
- BJ fibroblasts were plated at a density of 20000 cells/cm 2 into 48-well plates and cultured to confluency (3 to 4 days).
- the HUVECs were plated on top of confluent fibroblast cultures at a density of 4000 cells/cm 2 .
- the culture medium was changed to EGM-2 medium (from EGM-2 bullet kit, Lonza). The next day, par- aliei co-cultures were treated differently:
- EBM-2 Endothelial cell basal medium
- Positive control A EBM-2 supplemented with 10 ng/ml VEGF (R&D Systems) and 1 ng/ml FGF-2 (Sigma); [0082] 3) Positive control B: EBM-2 supplemented with 50 ng/ml
- EBM-2 supplemented with 440 ⁇ g/ml (protein concentration; approximately 25% of the total volume of cell culture medium) of ATE;
- EBM-2 supplemented with 880 ⁇ g/ml (protein concentra- tion; approximately 50% of the total volume of cell culture medium) of ATE;
- EBM-2 supplemented with 1320 ⁇ g/ml (protein concentration; approximately 75% of the total volume of cell culture medium) of ATE.
- ATE used in the experiment was prepared as de- scribed in Example 1 and contained 1 .76 mg/ml protein, 143.4 pg/ml IGF-I, 123.1 pg/mi FGF-2, and 3.56 pg/ml VEGF.
- the cells were cultured for seven days prior to immunocyto- chemical staining with an endothelial ceil specific antibody (anti-von Wiilebrand factor).
- the media were changed once during the culture.
- lmmunocytochemical staining was performed as follows: Cells were washed three times with PBS, fixed with ice-cold 70% ethanol for 20 minutes, permeabilized with 0.5% Triton X-100 (JT Baker, Phiilipsburg, NJ, USA) for 15 minutes, and blocked for unspecific staining with 10% BSA (Gibco) for 30 minutes. After blocking, the cells were incubated with a von WilSebrand Factor primary antibody (anti-vWF produced in rabbit, Sigma, 1 :500) at 4 0 C overnight.
- a von WilSebrand Factor primary antibody anti-vWF produced in rabbit, Sigma, 1 :500
- the adipose tissue extract induced a formation of tube-like structures in the co-cultures from day 4 or 5. After seven days, a dear tube formation was observed in positive controls A and B ( Figures 3 E and 3F, respectively) and in cells treated with 880 ⁇ g/ml ( Figure 3C) or 1320 ⁇ g/ml ( Figure 3D) of ATE. Growth factor treatment in positive control A clearly stimulated the formation of typical long, thin, branched capillary like structures. Any excess amount of growth factors in positive control B, however, resulted in somewhat disorganized or clustered tube structures. Growth factor treatment in positive control A represented an in vivo situation in a tissue.
- the adipose tissue extract produced a dose-dependent effect on the HUVEC cells and produced a network of capillaries.
- Two different injectable implants according to the present in- vention were formulated for animal studies: 1 ) an implant comprising 54.5% rat ATE (tota! protein concentration 1.3 mg/ml) and 45.5% hyaluronic acid; and 2) an implant comprising 54.5% human ATE (total protein concentration 2.5 mg/ml) and 45.5% hyaluronic acid, in these formulations, the hyaluronic acid used was a non-animal derived stabilized hyaluronic acid (NASHA) 20 mg/mi, Restyiane (Q-Med, Uppsala, Sweden).
- NASHA non-animal derived stabilized hyaluronic acid
- Different forms of crosslinked hyaluronic products e.g. Restyiane Perlane or Restyiane Touch or Macrolane may also be used, depending on the type of the defect.
- Implants were prepared by mixing 1 ml of Restyiane carefully with 1.2 ml of ATE (prepared as described in Example 1 ). The final implant volume placed under subcutis of rats was always 100 ⁇ l and consisted of 45.5 ⁇ l of hyaluronic acid and 54.5 ⁇ l of incorporated liquid. Such implants are viscous enough to avoid immediate resorption into a tissue or leakage from an injection site, but contain a high amount of the extract.
- Ketalar (10 mg/ml; 75 mg/kg). Implants and controls prepared as described in
- Example 4 were injected under dorsal subcutis of the rats with a 1 ml syringe and a 27 gauge needle in a final volume of 100 ⁇ l. Implants were left under subcutis for 1 , 2, 3, 4, 6, 8, 12 or 20 weeks and for 9 months, after which the animals were sacrificed with carbon dioxide. Tissue samples were taken from the implantation sites and processed for histological analysis.
- the human ATE used in the experiment was prepared as described in Example 1 and con- tained 2.5 mg/ml protein, 200 pg/m! IGF-1 , 863 pg/ml FGF-2, and 61 pg/ml VEGF.
- the Rat ATE used in the experiment was prepared as described in Example 1 and contained 1 .3 mg/mi protein.
- tissue samples were fixed in 4% paraformaldehyde overnight, dehydrated with a graded ethanol series and embedded in paraffin. Specimens were cut into 5 ⁇ M thick slices with microtome ⁇ Microm HM 430, Microm GmbH, Waldorf, Germany) and stained with hematoxylin-eosin (H&E) for histological analysis. Images were taken with a Nikon Microphot FXA microscope (Nikon, Tokyo, Japan) and processed using Corel Draw 10 and Adobe Photoshop 7.0. [0097] Hematoxylin-eosin staining of the histological specimens revealed neovascularization and adipose tissue formation in the implant area ⁇ Fig. 4 and Fig. 5).
- Example 6 Clinical pretrial [0099] Human adipose tissue extract was prepared from a liposuction sample by direct suction into a sterile syringe. To maximize protein extraction, 2.5 ml of the liposuctioned fat was mixed with 1.5 ml of sterile isotonic salt solution in a sterile syringe and incubated for 45 minutes in room temperature. The syringe was shaken several times during incubation. The total protein concentration of the resulting extract was 2.5 mg/ml, and growth factor concentrations were 17 pg/ml VEGF and 177 pg/ml FGF-2.
- the extract was sterile filtered through a 0.2 ⁇ m filter (Acrodisc syringe filter, Pail Gelman Laboratory, An Arbor, USA) into a second sterile syringe connected via an adapter to the first syringe.
- the second syringe now containing the extract was connected with an adapter to a third sterile syringe containing adequate amount of Restylane.
- the resulting sterile adipose tissue extract was mixed with Restylane, the ratio being 0.9 ml (45.5%) of Restylane and 1.2 ml (54.5%) of the adipose tissue extract.
- the iiquid and gel phases were mixed by injecting the material back and forth be- tween the second and the third syringes.
- the implant material was considered to be homogenous enough, when the pale pink color of the adipose tissue extract was suspended evenly in the material.
- the final implant contained 1.2 mg/ml protein.
- the implant obtained was immediately injected with a 30 G needle subcutaneously into two different sites in a leg of a healthy volunteer.
- the first site comprised old, existing scar tissue, and 450 ⁇ l of the implant was injected therein.
- the second site in the leg was provided with two defects by removing subcutaneous fat tissue, such that the resuiting round defect sites in the tissue were approximately 1 cm in diameter.
- One defect was left intact, as a control, whereas the other defect was filled with 900 ⁇ l of the implant.
- the present invention provides an implant which induces de novo adipose tissue formation and angiogenesis, and provides a long-term delivery system of adipogenic and angiogenic factors that have been captured and immobilized into a hydrogel structure.
- the bioactive implant of the present invention aids in the induction of host cell infiltration and enables more efficient tissue regeneration.
- the effects of the implants are local and site-specific, reducing overall doses of adipogenic and angiogeninc factors required for a certain effect. Not only is this cost-effective but also a way to avoid harmful systemic effects.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Cell Biology (AREA)
- Transplantation (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Dispersion Chemistry (AREA)
- Botany (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0918851-7A BRPI0918851B1 (en) | 2008-09-08 | 2009-09-07 | IMPLANT AND METHODS FOR PREPARING A CELL FREE TISSUE EXTRACT AND FOR PREPARING AN IMPLANT CONTAINING THE ABOVE EXTRACT |
ES09811160T ES2790300T3 (en) | 2008-09-08 | 2009-09-07 | Methods and means for soft tissue engineering |
JP2011525584A JP2012502012A (en) | 2008-09-08 | 2009-09-07 | Methods and means for soft tissue engineering |
EP09811160.2A EP2337568B1 (en) | 2008-09-08 | 2009-09-07 | Methods and means for soft tissue engineering |
LTEP09811160.2T LT2337568T (en) | 2008-09-08 | 2009-09-07 | Methods and means for soft tissue engineering |
CN2009801348777A CN102143755A (en) | 2008-09-08 | 2009-09-07 | Methods and means for soft tissue engineering |
DK09811160.2T DK2337568T3 (en) | 2008-09-08 | 2009-09-07 | METHODS AND MEASURES FOR SOFTWARE TECHNOLOGY |
PL09811160T PL2337568T3 (en) | 2008-09-08 | 2009-09-07 | Methods and means for soft tissue engineering |
US13/040,957 US9056084B2 (en) | 2008-09-08 | 2011-03-04 | Methods and means for soft tissue engineering |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9519808P | 2008-09-08 | 2008-09-08 | |
US61/095,198 | 2008-09-08 | ||
FI20085839 | 2008-09-08 | ||
FI20085839A FI20085839A0 (en) | 2008-09-08 | 2008-09-08 | Methods and tools for soft tissue technology |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/040,957 Continuation US9056084B2 (en) | 2008-09-08 | 2011-03-04 | Methods and means for soft tissue engineering |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010026299A1 true WO2010026299A1 (en) | 2010-03-11 |
Family
ID=39852230
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FI2009/050715 WO2010026299A1 (en) | 2008-09-08 | 2009-09-07 | Methods and means for soft tissue engineering |
Country Status (12)
Country | Link |
---|---|
US (1) | US9056084B2 (en) |
EP (1) | EP2337568B1 (en) |
JP (1) | JP2012502012A (en) |
CN (1) | CN102143755A (en) |
BR (1) | BRPI0918851B1 (en) |
DK (1) | DK2337568T3 (en) |
ES (1) | ES2790300T3 (en) |
FI (1) | FI20085839A0 (en) |
LT (1) | LT2337568T (en) |
PL (1) | PL2337568T3 (en) |
PT (1) | PT2337568T (en) |
WO (1) | WO2010026299A1 (en) |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011135380A1 (en) * | 2010-04-29 | 2011-11-03 | Nhs Blood & Transplant | Method for evaluating angiogenic potential |
WO2013138864A1 (en) * | 2012-03-23 | 2013-09-26 | Neopec Pty Ltd | Tissue scaffold |
WO2012112757A3 (en) * | 2011-02-17 | 2014-01-09 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
EP2802308A1 (en) * | 2012-01-13 | 2014-11-19 | Allergan, Inc. | Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation |
US8894992B2 (en) | 2010-08-19 | 2014-11-25 | Allergan, Inc. | Compositions and soft tissue replacement methods |
US8900571B2 (en) | 2010-08-19 | 2014-12-02 | Allergan, Inc. | Compositions and soft tissue replacement methods |
US8926963B2 (en) | 2010-08-19 | 2015-01-06 | Allergan, Inc. | Compositions and soft tissue replacement methods |
US9149422B2 (en) | 2011-06-03 | 2015-10-06 | Allergan, Inc. | Dermal filler compositions including antioxidants |
US9248384B2 (en) | 2013-10-02 | 2016-02-02 | Allergan, Inc. | Fat processing system |
US9662422B2 (en) | 2011-09-06 | 2017-05-30 | Allergan, Inc. | Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation |
US9795711B2 (en) | 2011-09-06 | 2017-10-24 | Allergan, Inc. | Hyaluronic acid-collagen matrices for dermal filling and volumizing applications |
US9867939B2 (en) | 2013-03-12 | 2018-01-16 | Allergan, Inc. | Adipose tissue combinations, devices, and uses thereof |
US10265477B2 (en) | 2013-05-23 | 2019-04-23 | Allergan, Inc. | Mechanical syringe accessory |
WO2019053503A3 (en) * | 2017-09-14 | 2019-06-06 | Genlife Sagl | Catalyst for the regeneration of tissues and related method for making it |
US10433928B2 (en) | 2015-03-10 | 2019-10-08 | Allergan Pharmaceuticals Holdings (Ireland) Unlimited Company | Multiple needle injector |
US10463595B2 (en) | 2008-09-02 | 2019-11-05 | Allergan Holdings France S.A.S. | Threads of hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof |
US10596321B2 (en) | 2016-04-08 | 2020-03-24 | Allergan, Inc. | Aspiration and injection device |
US10722444B2 (en) | 2014-09-30 | 2020-07-28 | Allergan Industrie, Sas | Stable hydrogel compositions including additives |
US10792427B2 (en) | 2014-05-13 | 2020-10-06 | Allergan, Inc. | High force injection devices |
US10806821B2 (en) | 2010-01-13 | 2020-10-20 | Allergan Industrie, Sas | Heat stable hyaluronic acid compositions for dermatological use |
US10905797B2 (en) | 2010-03-22 | 2021-02-02 | Allergan, Inc. | Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation |
US10994049B2 (en) | 2011-06-03 | 2021-05-04 | Allergan Industrie, Sas | Dermal filler compositions for fine line treatment |
US11000626B2 (en) | 2011-06-03 | 2021-05-11 | Allergan Industrie, Sas | Dermal filler compositions including antioxidants |
US11083684B2 (en) | 2011-06-03 | 2021-08-10 | Allergan Industrie, Sas | Dermal filler compositions |
CN115044541A (en) * | 2022-05-24 | 2022-09-13 | 南京农业大学 | High-differentiation-efficiency immortalized pig fat precursor cell line and construction method and application thereof |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112012020886B1 (en) | 2010-03-04 | 2018-02-06 | Ajinomoto Co. , Inc. | COFFEE BLINDER, PROCESS TO PRODUCE THIS, AND PROCESS TO PRODUCE A DRINK. |
US9352003B1 (en) | 2010-05-14 | 2016-05-31 | Musculoskeletal Transplant Foundation | Tissue-derived tissuegenic implants, and methods of fabricating and using same |
US8883210B1 (en) | 2010-05-14 | 2014-11-11 | Musculoskeletal Transplant Foundation | Tissue-derived tissuegenic implants, and methods of fabricating and using same |
US10130736B1 (en) | 2010-05-14 | 2018-11-20 | Musculoskeletal Transplant Foundation | Tissue-derived tissuegenic implants, and methods of fabricating and using same |
EP2726056A4 (en) * | 2011-06-28 | 2015-01-14 | Veris Medical Inc | System and method for collagen isolation |
EP2687224A1 (en) * | 2012-07-19 | 2014-01-22 | Tissue Med Biosciences Forschungs- und Entwicklungsgesellschaft mbH | Medicament for wound treatment |
EP3016516A4 (en) * | 2013-07-01 | 2017-03-22 | Amit Prakash Govil | Soft tissue implant |
US20150037436A1 (en) | 2013-07-30 | 2015-02-05 | Musculoskeletal Transplant Foundation | Acellular soft tissue-derived matrices and methods for preparing same |
EP3297694A1 (en) | 2015-05-21 | 2018-03-28 | Musculoskeletal Transplant Foundation | Modified demineralized cortical bone fibers |
US10912864B2 (en) | 2015-07-24 | 2021-02-09 | Musculoskeletal Transplant Foundation | Acellular soft tissue-derived matrices and methods for preparing same |
US11052175B2 (en) | 2015-08-19 | 2021-07-06 | Musculoskeletal Transplant Foundation | Cartilage-derived implants and methods of making and using same |
EP3335696B1 (en) * | 2016-12-15 | 2019-12-18 | UPM-Kymmene Corporation | A method for drying cell-free tissue extract in a hydrogel comprising nanofibrillar cellulose and a dried hydrogel comprising nanofibrillar cellulose and cell-free tissue extract |
CN110496241A (en) * | 2018-05-16 | 2019-11-26 | 上海交通大学医学院附属第九人民医院 | It is derived from the biomaterial and its preparation method and application of adipose tissue |
CN112675153A (en) * | 2019-10-17 | 2021-04-20 | 上海萨美细胞技术有限公司 | Application of acellular adipose tissue extract in promoting hair growth and fixing hair |
CN113398331A (en) * | 2021-05-25 | 2021-09-17 | 郑州市和沐生物科技有限公司 | Cell-free fat extract, and preparation method and analysis method thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006029262A2 (en) * | 2004-09-08 | 2006-03-16 | Myocardial Therapeutics, Inc. | Conditioned medium of autologous or allogenic progenitor cells for angiogenesis treatment |
US20060153797A1 (en) * | 2004-06-11 | 2006-07-13 | Bortolotto Susan K | Tissue material and matrix |
WO2008041909A1 (en) * | 2006-10-02 | 2008-04-10 | Norrfors Searl | A method of producing native components, such as growth factors or extracellular matrix proteins, through cell culturing of tissue samples for tissue repair |
WO2009102452A2 (en) * | 2008-02-11 | 2009-08-20 | The Johns Hopkins University | Compositions and methods for implantation of adipose tissue and adipose tissue products |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2004260638A1 (en) * | 2003-06-18 | 2005-02-10 | Macropore Biosurgery Inc. | Methods of using adipose tissue-derived cells in augmenting autologous fat transfer |
-
2008
- 2008-09-08 FI FI20085839A patent/FI20085839A0/en not_active Application Discontinuation
-
2009
- 2009-09-07 EP EP09811160.2A patent/EP2337568B1/en active Active
- 2009-09-07 WO PCT/FI2009/050715 patent/WO2010026299A1/en active Application Filing
- 2009-09-07 JP JP2011525584A patent/JP2012502012A/en active Pending
- 2009-09-07 BR BRPI0918851-7A patent/BRPI0918851B1/en active IP Right Grant
- 2009-09-07 ES ES09811160T patent/ES2790300T3/en active Active
- 2009-09-07 PT PT98111602T patent/PT2337568T/en unknown
- 2009-09-07 DK DK09811160.2T patent/DK2337568T3/en active
- 2009-09-07 LT LTEP09811160.2T patent/LT2337568T/en unknown
- 2009-09-07 CN CN2009801348777A patent/CN102143755A/en active Pending
- 2009-09-07 PL PL09811160T patent/PL2337568T3/en unknown
-
2011
- 2011-03-04 US US13/040,957 patent/US9056084B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060153797A1 (en) * | 2004-06-11 | 2006-07-13 | Bortolotto Susan K | Tissue material and matrix |
WO2006029262A2 (en) * | 2004-09-08 | 2006-03-16 | Myocardial Therapeutics, Inc. | Conditioned medium of autologous or allogenic progenitor cells for angiogenesis treatment |
WO2008041909A1 (en) * | 2006-10-02 | 2008-04-10 | Norrfors Searl | A method of producing native components, such as growth factors or extracellular matrix proteins, through cell culturing of tissue samples for tissue repair |
WO2009102452A2 (en) * | 2008-02-11 | 2009-08-20 | The Johns Hopkins University | Compositions and methods for implantation of adipose tissue and adipose tissue products |
Non-Patent Citations (1)
Title |
---|
URIEL S. ET AL: "The role of adipose protein derived hydrogels in adipogenesis", BIOMATERIALS, vol. 29, no. 27, 2008, pages 3712 - 3719, XP022849900 * |
Cited By (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10463595B2 (en) | 2008-09-02 | 2019-11-05 | Allergan Holdings France S.A.S. | Threads of hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof |
US11154484B2 (en) | 2008-09-02 | 2021-10-26 | Allergan Holdings France S.A.S. | Threads of hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof |
US10806821B2 (en) | 2010-01-13 | 2020-10-20 | Allergan Industrie, Sas | Heat stable hyaluronic acid compositions for dermatological use |
US10905797B2 (en) | 2010-03-22 | 2021-02-02 | Allergan, Inc. | Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation |
WO2011135380A1 (en) * | 2010-04-29 | 2011-11-03 | Nhs Blood & Transplant | Method for evaluating angiogenic potential |
US8926963B2 (en) | 2010-08-19 | 2015-01-06 | Allergan, Inc. | Compositions and soft tissue replacement methods |
US8894992B2 (en) | 2010-08-19 | 2014-11-25 | Allergan, Inc. | Compositions and soft tissue replacement methods |
US8900571B2 (en) | 2010-08-19 | 2014-12-02 | Allergan, Inc. | Compositions and soft tissue replacement methods |
WO2012112757A3 (en) * | 2011-02-17 | 2014-01-09 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
US9149422B2 (en) | 2011-06-03 | 2015-10-06 | Allergan, Inc. | Dermal filler compositions including antioxidants |
US10994049B2 (en) | 2011-06-03 | 2021-05-04 | Allergan Industrie, Sas | Dermal filler compositions for fine line treatment |
US11000626B2 (en) | 2011-06-03 | 2021-05-11 | Allergan Industrie, Sas | Dermal filler compositions including antioxidants |
US10624988B2 (en) | 2011-06-03 | 2020-04-21 | Allergan Industrie, Sas | Dermal filler compositions including antioxidants |
US11083684B2 (en) | 2011-06-03 | 2021-08-10 | Allergan Industrie, Sas | Dermal filler compositions |
US9782517B2 (en) | 2011-09-06 | 2017-10-10 | Allergan, Inc. | Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation |
US11844878B2 (en) | 2011-09-06 | 2023-12-19 | Allergan, Inc. | Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation |
US11833269B2 (en) | 2011-09-06 | 2023-12-05 | Allergan, Inc. | Hyaluronic acid-collagen matrices for dermal filling and volumizing applications |
US9821086B2 (en) | 2011-09-06 | 2017-11-21 | Allergan, Inc. | Hyaluronic acid-collagen matrices for dermal filling and volumizing applications |
US9795711B2 (en) | 2011-09-06 | 2017-10-24 | Allergan, Inc. | Hyaluronic acid-collagen matrices for dermal filling and volumizing applications |
US9662422B2 (en) | 2011-09-06 | 2017-05-30 | Allergan, Inc. | Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation |
EP2802308A1 (en) * | 2012-01-13 | 2014-11-19 | Allergan, Inc. | Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation |
WO2013138864A1 (en) * | 2012-03-23 | 2013-09-26 | Neopec Pty Ltd | Tissue scaffold |
US9867939B2 (en) | 2013-03-12 | 2018-01-16 | Allergan, Inc. | Adipose tissue combinations, devices, and uses thereof |
US10265477B2 (en) | 2013-05-23 | 2019-04-23 | Allergan, Inc. | Mechanical syringe accessory |
US9248384B2 (en) | 2013-10-02 | 2016-02-02 | Allergan, Inc. | Fat processing system |
US10369500B2 (en) | 2013-10-02 | 2019-08-06 | Allergan, Inc. | Fat processing system |
US10792427B2 (en) | 2014-05-13 | 2020-10-06 | Allergan, Inc. | High force injection devices |
US10722444B2 (en) | 2014-09-30 | 2020-07-28 | Allergan Industrie, Sas | Stable hydrogel compositions including additives |
US10433928B2 (en) | 2015-03-10 | 2019-10-08 | Allergan Pharmaceuticals Holdings (Ireland) Unlimited Company | Multiple needle injector |
US10596321B2 (en) | 2016-04-08 | 2020-03-24 | Allergan, Inc. | Aspiration and injection device |
US11890457B2 (en) | 2016-04-08 | 2024-02-06 | Allergan, Inc. | Aspiration and injection device |
WO2019053503A3 (en) * | 2017-09-14 | 2019-06-06 | Genlife Sagl | Catalyst for the regeneration of tissues and related method for making it |
US12023358B2 (en) | 2017-09-14 | 2024-07-02 | Genlife Sagl | Catalyst for the regeneration of tissues and related method for making it |
CN115044541A (en) * | 2022-05-24 | 2022-09-13 | 南京农业大学 | High-differentiation-efficiency immortalized pig fat precursor cell line and construction method and application thereof |
CN115044541B (en) * | 2022-05-24 | 2023-08-15 | 南京农业大学 | Immortalized pig fat precursor cell line with high differentiation efficiency, and construction method and application thereof |
Also Published As
Publication number | Publication date |
---|---|
US20110151005A1 (en) | 2011-06-23 |
FI20085839A0 (en) | 2008-09-08 |
EP2337568A1 (en) | 2011-06-29 |
DK2337568T3 (en) | 2020-05-11 |
EP2337568A4 (en) | 2014-02-19 |
PT2337568T (en) | 2020-05-15 |
CN102143755A (en) | 2011-08-03 |
ES2790300T3 (en) | 2020-10-27 |
LT2337568T (en) | 2020-05-25 |
US9056084B2 (en) | 2015-06-16 |
PL2337568T3 (en) | 2020-08-10 |
BRPI0918851B1 (en) | 2019-06-25 |
BRPI0918851A2 (en) | 2015-12-08 |
JP2012502012A (en) | 2012-01-26 |
EP2337568B1 (en) | 2020-02-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2337568B1 (en) | Methods and means for soft tissue engineering | |
US11369716B2 (en) | Reparative cell isolation and delivery | |
Cho et al. | Engineering of volume-stable adipose tissues | |
CA2702173C (en) | Preparation for treating heart disease used in cell therapy | |
JP2019038833A (en) | Compositions and methods for cardiac therapy | |
US20120264190A1 (en) | Decellularized and Delipidized Extracellular Matrix and Methods of Use | |
AU2007265862A1 (en) | Soft tissue filler composition comprising autologous dermis-derived cell culture product and hyaluronic acid | |
US7186557B2 (en) | Methods of producing neurons | |
Phillips et al. | An angiogenic extract from skeletal muscle stimulates monocyte and endothelial cell chemotaxis in vitro | |
Palakkara et al. | Healing potential of chitosan and decellularized intestinal matrix with mesenchymal stem cells and growth factor in burn wound in rat | |
US20220339202A1 (en) | Regenerative bioactive suspension derived from freshly disaggregated tissue and methods of use in clinical therapies | |
CN107326005B (en) | Dermis construction method without exogenous scaffold and culture solution | |
WO2013138864A1 (en) | Tissue scaffold | |
Zhang et al. | Evaluation of the Composite Skin Patch Loaded with Bioactive Functional Factors Derived from Multicellular Spheres of EMSCs for Regeneration of Full-thickness Skin Defects in Rats | |
Costantini et al. | 3D tissue modelling of skeletal muscle tissue | |
Voigt et al. | Human recombinant EGF protein delivered by a biodegradable cell transplantation system | |
Kadir | Engineering Mesenchymal Stem Cell Paracrine Signaling for Cartilage Regeneration | |
Hu et al. | Microencapsulated nerve growth factor-expressing NIH3T3 cells-incorporated tissue engineering skin: a preliminary study | |
CELIKKIN et al. | 3D Tissue Modelling of Skeletal Muscle Tissue | |
Lin et al. | The Co-Culture of ASCs and EPCs Promotes Wound Healing by Promoting Angiogenesis in Full Thickness Skin Defects | |
Galea et al. | Engineering of Adipose Tissue | |
Lydic | Characteristics of Rabbit and Rat Mesenchymal Stromal Cell Growth and Attachment to Mesh Used in Hernia Repair | |
KEDEM et al. | VEGF-Releasing Scaffolds Enhance Vascularization and Engraftment of Transplanted Hepatocytes | |
Priscilla | BONE MARROW STEM CELL BASED TISSUE MODULATING STRATEGY FOR WOUND HEALING | |
MXPA05013486A (en) | Pyrazoloisoquinoline derivatives as kinase inhibitors. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980134877.7 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09811160 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 350/MUMNP/2011 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2011525584 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009811160 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0918851 Country of ref document: BR Kind code of ref document: A2 Effective date: 20110304 |